MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER;LEAD DISCOVERY CENTER GMBH
发明人:
SCHULTZ-FADEMRECHT CARSTEN,KLEBL BERT,CHOIDAS AXEL,KOCH UWE,EICKHOFF JAN,WOLF ALEXANDER,ULLRICH AXEL
申请号：
ZA201300533
公开号：
ZA201300533B
申请日:
2013.01.21
申请国别(地区):
ZA
年份:
2014
代理人:
摘要：
The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides of general formula (I): and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.
